Loading article…
Synapse collapse puts over 10 million accounts at risk; CFPB will reimburse $46 M to victims of Yotta, Juno, Copper and other fintechs.
Synapse Financial Technologies filed for Chapter 7 liquidation, leaving more than 10 million user accounts in limbo and prompting the Consumer Financial Protection Bureau to allocate $46.2 million for victim reimbursements [1][2].
| At a glance | |
|---|---|
| Accounts impacted | >10 million |
| Bankruptcy type | Chapter 7 liquidation |
| CFPB reimbursement | $46,248,291 |
| Key fintechs affected | Yotta, Juno, Copper, MicroVentures, Mainvest |
Synapse, once hailed by CNBC as a top fintech, powered digital banking services for dozens of platforms, including savings app Yotta, crypto investing app Juno, teen‑banking app Copper, and crowdfunding sites MicroVentures and Mainvest. Its sudden shift from Chapter 11 reorganization to Chapter 7 liquidation has frozen access to funds held through its partner, Evolve Bank & Trust, which disabled the system without notice [1]. The fallout has forced platforms to scramble for alternative banking solutions; MicroVentures, for example, moved $850 million of investor funds away from Synapse in late 2023 and built its own services after a failed transition to other BaaS providers [1].
The CFPB announced it will draw from its Civil Penalty Fund to reimburse victims, citing a shortfall of $60‑$90 million in end‑user accounts uncovered during bankruptcy hearings [2]. The agency’s single‑line allocation of $46,248,291 reflects the first tranche of compensation, though it remains unclear whether the full shortfall will be covered [2]. The CFPB’s complaint alleges Synapse “failed to maintain adequate records of the location of consumers’ funds,” a breach that underscores growing regulatory scrutiny of bank‑fintech partnerships [2].
The Synapse debacle has already strained other fintechs. Mainvest, a FINRA‑regulated funding portal, is winding down operations partly because Evolve froze payment processing for Synapse users, affecting “hundreds of other clients representing ~10 million end users” [1][3]. Yieldstreet’s disclosures note reliance on Synapse for certain services, though it stresses that Synapse is not a bank and that accounts are held by Evolve [1]. These disruptions highlight the systemic risk posed by a single BaaS provider’s failure.
Synapse’s collapse serves as a cautionary tale for the fintech ecosystem: reliance on a single banking‑as‑a‑service platform can jeopardize millions of users, and regulators are poised to tighten guardrails to prevent similar failures. The ultimate resolution will depend on how quickly victims are repaid and whether the industry adopts more resilient banking partnerships.
Coverage is mostly measured — 8 of 8 reports stay neutral.
Every Monday — the token unlocks, Fed dates & catalysts set to move crypto and markets this week. So you’re never blindsided.
Free · 3-min read · one-click unsubscribe
AI-assisted synthesis by the TrendWatcher Editorial Desk · sourced from 3 outlets · Jun 18, 2026 · How we report
A report by trustee Jelena McWilliams indicates an $85 million discrepancy between the $265 million in customer balances and the $180 million held by partner banks, but the exact source of the missing funds is still unknown.
More than 100,000 customers of various fintech companies that used Synapse have been locked out of their savings accounts.
The trial showed consistent signals of benefit in functional endpoints, including improved hand grip strength and motor function, with effects persisting up to seven days after treatment ended.
Ignaseclant was reported as well tolerated, with all adverse events classified as mild or moderate and no serious adverse events or discontinuations.
NMD Pharma plans to conduct larger and longer-term studies to further evaluate ignaseclant’s efficacy and safety in Charcot‑Marie‑Tooth disease.